Biotricity Inc

Greetings and welcome to the Biotricity Fiscal Year 2024 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Paul Koontz, Investor Relations. Thank you, Paul. You may begin.

Thank you, and good afternoon, everyone. As a reminder, Biotricity's fourth quarter and fiscal year 2024 ended on March 31st, 2024, so all figures presented for this period will reflect that end date. Earlier today, Biotricity issued its earnings press release for the period, which highlighted financial and operational results. A copy of the press release is available on the Investor Relations section of the Biotricity website, and the full financials have been filed with the SEC on Form 10-K and posted on EDGAR, which you can find at www.sec.gov. Before beginning the company's formal remarks, I'd like to remind listeners that today's discussion may contain forward-looking statements that reflect management's current views with respect to future events. Any such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. Biotricity does not undertake to update any forward-looking statements except as required. At this point, I am pleased to turn the call over to Biotricity's founder and CEO, Dr. Makas Al-Sadiq. Please go ahead.

Thank you, and thank you everybody for joining us today. Fiscal 2024 has been a transformative year for Biotricity, marked by significant advancements and strategic initiatives that have positioned us on a clear path to profitability and positive EBITDA. We have increased revenue, significantly improved margins, and reduced EBITDA losses by almost half. Our commitment to innovation, strategic partnerships, and operational efficiency has allowed us to make remarkable progress across multiple fronts. One of our most significant achievements this year has been the expansion of our cardiac AI cloud platform. This initiative, powered by strategic partnerships with industry giants such as Amazon AWS and Google's TensorFlow, leverages over 500 billion heartbeats of anonymized data. Our AI-driven platform is designed to enhance diagnostic accuracy, improve patient outcomes, and increase clinic profitability. As we pursue FDA clearance for our groundbreaking AI clinical model, We are setting new standards in cardiac care, ensuring every patient receives the highest quality of care. Our recent strategic alliances with three of the top group purchasing organizations, otherwise known as GPOs, has been pivotal. These partnerships provide us access to approximately 90% of all hospitals in the US, significantly expanding our market reach. We have a robust pipeline that is growing and active with active pilots at major groups around the country. This positions us to capitalize on expansive market channels and secure advantageous terms for medical devices and supplies, strengthening our presence in the healthcare technology sector. Moreover, the Health Canada approval for our BioCore device has opened new avenues for revenue growth outside of the US in the $1.56 billion Canadian cardiology devices market. This approval aligns perfectly with our strategy to promote accessible high-quality care, and improved patient outcomes. During the fourth quarter, we also launched the BioCore Pro, a next-generation cardiac monitoring device, and entered into several key partnerships, including a collaboration with HealthAid Africa to provide complementary heart health screenings at high-profile events. These initiatives underscore our commitment to expanding our market footprint and delivering innovative solutions. Looking beyond fiscal 2024, our recent initiatives continue to build momentum. We have launched a major cardiac monitoring pilot program with a network of nine hospitals and 10 clinics, and we are accelerating our path to break even with the rapid adoption of our BioCorp probe by both existing and new customers. Additionally, our strategic entry into the pulmonary and neurology fields through partnerships with leading home-based diagnostic companies marks a significant diversification of our market reach. Furthermore, we are extremely excited about the recent launch of HeartSecure, our direct-to-consumer heart health screening service. This service targets the $1.1 billion home heart health market and represents our commitment to making heart health services more accessible in response to the global challenge posed by cardiovascular disease. In summary, our strategic initiatives, technological advancements, and operational efficiencies have positioned Biotricity for sustained growth and profitability. We remain focused on delivering innovative, high-quality cardiac care solutions and are confident in our ability to continue driving value for our shareholders and improving patient outcomes globally. With that, I will turn the call over to our CFO, John Iannoglou, to provide more detailed financial insights.